Glimepiride tablet

A technology for glimepiride tablets and urea tablets, which is applied in the field of medicine, can solve the problems of easy aggregation, increased gastrointestinal side effects, and difficulty in ensuring uniform mixing of drugs, and achieves the effects of simple process and fast dissolution rate.

Active Publication Date: 2015-04-29
SHANDONG NEWTIME PHARMA
View PDF9 Cites 3 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, after the drug is micronized, it is easy to aggregate, and it is difficult to ensure that the ...

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Glimepiride tablet
  • Glimepiride tablet
  • Glimepiride tablet

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] prescription:

[0024]

[0025] Preparation Process:

[0026] Dissolve glimepiride in diethylene glycol monoethyl ether, add hydroxypropyl cellulose, stir to dissolve, then add diatomaceous earth in the prescribed amount for adsorption, and then mix with lactose, sodium carboxymethyl starch, stearic acid Magnesium is homogeneously mixed and compressed using the direct compression process.

Embodiment 2

[0028] prescription:

[0029]

[0030]

[0031] Preparation Process:

[0032] Dissolve glimepiride in diethylene glycol monoethyl ether, add hydroxypropyl cellulose, stir to dissolve, then add diatomaceous earth in the prescribed amount for adsorption, and then mix with microcrystalline cellulose, crospovidone, Magnesium stearate is mixed evenly and compressed by direct compression process.

Embodiment 3

[0034] prescription:

[0035]

[0036] Preparation Process:

[0037] Dissolve glimepiride in diethylene glycol monoethyl ether, add hydroxypropyl cellulose, stir to dissolve, then add diatomaceous earth in the prescribed amount for adsorption, and then mix with microcrystalline cellulose, crospovidone, Magnesium stearate is mixed evenly and compressed by direct compression process.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the technical field of medicine, and particularly relates to a glimepiride tablet. The glimepiride tablet contains glimepiride, hydroxypropyl cellulose and vapor-phase silicon dioxide. The preparation method comprises the following steps: dissolving the glimepiride and hydroxypropyl cellulose in diethylene glycol monoethyl ether, adding the vapor-phase silicon dioxide for adsorption, uniformly mixing pharmaceutically acceptable auxiliary materials, and directly tabletting. Compared with the prior art, the glimepiride tablet has the advantages of high drug dissolution rate and simple technique, does not need to add any surfactant, and does not need micronization treatment.

Description

technical field [0001] The invention belongs to the technical field of medicine, and in particular relates to a glimepiride tablet. Background technique [0002] Glimepiride is a new sulfonylurea hypoglycemic drug, the chemical name is 1-[4-[2-(3-ethyl-4-methyl-2-oxo-3-pyrroline) -1-formamido)ethyl]benzenesulfonyl]-3-(trans-4-methylcyclohexyl)urea, molecular formula: C 24 h 34 N 4 o 5 S, molecular weight: 490.62, structural formula as follows: [0003] [0004] Glimepiride was developed by the German company Hoechst Marion Roussel (HMR). It was first launched in Sweden under the trade name Amaryl in September 1995. It was approved by the FDA to enter the US market in 1996. It is used for the treatment of uncontrolled diet and exercise. Type 2 diabetes, it is the first FDA-approved sulfonylurea drug that can be used simultaneously with insulin. Because the drug has a short action time with the receptor, it shortens the time for insulin secretion, so it has a strong i...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/20A61K47/46A61K31/64A61P3/10A61K47/38
Inventor 张贵民荣维燕张庆森
Owner SHANDONG NEWTIME PHARMA
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap